Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  ResMed, Inc.    RMD

RESMED, INC.

(RMD)
  Report
Delayed Quote. Delayed Nyse - 11/30 04:10:00 pm
209.6 USD   -0.02%
11/20RESMED INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
11/10RESMED, INC. : Ex-dividend day for
FA
11/05RESMED : Other Events (form 8-K/A)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Morgan Stanley : rates RMD as Equal-weight

10/25/2020 | 06:31pm EST

ResMed will publish its first quarter earnings on October 29. Morgan Stanley suspects the uplift from ventilators sales will have peaked in the fourth quarter and the positive revisions to earnings have played out for the short term.

The business is expected to emerge from the pandemic in good condition although the valuation keeps the broker's rating at Equal-weight. Target is raised to $25.90 from $25.40. Industry view: In-Line.

Sector: Health Care Equipment & Services.

Target price is $25.90.Current Price is $25.74. Difference: $0.16 - (brackets indicate current price is over target). If RMD meets the Morgan Stanley target it will return approximately 1% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2020 Acquisdata Pty Ltd., source FN Arena

Stocks mentioned in the article
ChangeLast1st jan.
MORGAN STANLEY -3.15% 61.83 Delayed Quote.20.95%
RESMED, INC. -0.02% 209.6 Delayed Quote.35.28%
All news about RESMED, INC.
11/20RESMED INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
11/10RESMED, INC. : Ex-dividend day for
FA
11/05RESMED : Other Events (form 8-K/A)
AQ
11/05RESMED : Underscores the Importance of Good Sleep with #WakeUpToGoodSleep Campai..
BU
11/03RESMED : Announces Participation in the Credit Suisse 29th Annual Global Healthc..
BU
11/02RESMED : Morgans rates RMD as Add
AQ
11/01RESMED : Home Health The Way Forward For ResMed
AQ
10/30RESMED : Management's Discussion and Analysis of Financial Condition and Results..
AQ
10/29RESMED : Fiscal 1Q Earnings Snapshot
AQ
10/29RESMED INC : Results of Operations and Financial Condition, Other Events, Financ..
AQ
More news
Financials (USD)
Sales 2021 3 141 M - -
Net income 2021 693 M - -
Net Debt 2021 248 M - -
P/E ratio 2021 44,6x
Yield 2021 0,76%
Capitalization 30 374 M 30 374 M -
EV / Sales 2021 9,75x
EV / Sales 2022 8,85x
Nbr of Employees 7 770
Free-Float 77,0%
Chart RESMED, INC.
Duration : Period :
ResMed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESMED, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 178,86 $
Last Close Price 209,60 $
Spread / Highest target 1,15%
Spread / Average Target -14,7%
Spread / Lowest Target -34,2%
EPS Revisions
Managers
NameTitle
Michael J. Farrell Chief Executive Officer & Director
Robert Andrew Douglas President & Chief Operating Officer
Peter C. Farrell Non-Executive Chairman
Brett A. Sandercock Chief Financial Officer
Carlos M. Nunez Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
RESMED, INC.35.28%30 380
THERMO FISHER SCIENTIFIC39.56%179 698
DANAHER CORPORATION41.24%153 996
INTUITIVE SURGICAL, INC.23.46%85 794
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.83.50%62 582
EDWARDS LIFESCIENCES CORPORATION9.64%53 138